title: Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
authors: Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
authors: Xingshun
authors: X
authors: Qi
authors: Jia
authors: J
authors: Jia
authors: Daiming
authors: D
authors: Fan
authors: Guohong
authors: G
authors: Han
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D016879:Salvage Therapy; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D014227:Triazines; D009536:Niacinamide; D000409:Alanine